FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2277185438> ?p ?o ?g. }

• W2277185438 endingPage "7524" @default.
• W2277185438 startingPage "7524" @default.
• W2277185438 abstract "7524 Background: While alkylating agents such as BCNU are active in melanoma, they give response rates of only 10–15%. BCNU induces DNA damage by formation of a chloroethyl adduct at the O6 position of guanine. This modification can be repaired by alkylguanine DNA alkyltransferase (AGT), and melanoma tumor cells can express high levels of AGT. O6BG is a potent inhibitor of AGT. We hypothesized that addition of O6BG would improve the clinical response to BCNU in patients with advanced melanoma. Methods: Patients had measurable disease, adequate organ function, PS≤ 2, and a corrected DLCO of ≥ 70% predicted. Patients were accrued into 2 cohorts based on whether or not they received prior chemotherapy. O6BG (120 mg/m2) was administered i.v. over 1 hour, followed by BCNU (40 mg/m2) i.v. over 1 hour, as an outpatient. PBMC were collected pre- O6BG and 18 hours later to assess for AGT depletion. Treatment cycles were repeated every 6 weeks and response using RECIST criteria was assessed every 2 cycles. Results: 42 patients were enrolled, 22 chemo-naive and 20 with prior chemo. In the chemo-naive cohort there were 1 CR, 4 SD, 13 PD, and 4 non-evaluable (NE) patients; the median time to progression (TTP) was 80d and the median survival (MS) was 211d. In the prior chemo cohort there were no objective responses, 3 SD, 15 PD, and 2 NE patients; the median TTP was 40d and the MS was 120d. The NE patients had clinical disease progression. AGT was effectively depleted from PBMC in the 15 patients tested (p<0.001). Grade 3/4 toxicities included thrombocytopenia (n=24), neutropenia (19), anemia (10), lymphopenia (7), fever (2), fatigue (2), hyponatremia (2), neuropathy (1), vomiting (1), decreased DLCO (1), and death (1). Toxicities were similar in the two cohorts. Conclusions: O6BG/BCNU was successfully administered on an outpatient basis and depleted AGT from PBMC. However, significant myelosuppression was seen and the clinical response rate was not greater than what is expected with BCNU alone. Although this regimen should not be explored further, administration of O6BG with other alkylating agents with greater single agent activity should be considered. No significant financial relationships to disclose." @default.
• W2277185438 created "2016-06-24" @default.
• W2277185438 creator A5023956757 @default.
• W2277185438 creator A5058735749 @default.
• W2277185438 creator A5063904421 @default.
• W2277185438 creator A5071756814 @default.
• W2277185438 creator A5075566772 @default.
• W2277185438 creator A5085317448 @default.
• W2277185438 date "2004-07-15" @default.
• W2277185438 modified "2023-09-25" @default.
• W2277185438 title "Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma" @default.
• W2277185438 doi "https://doi.org/10.1200/jco.2004.22.90140.7524" @default.
• W2277185438 hasPublicationYear "2004" @default.
• W2277185438 type Work @default.
• W2277185438 sameAs 2277185438 @default.
• W2277185438 citedByCount "1" @default.
• W2277185438 crossrefType "journal-article" @default.
• W2277185438 hasAuthorship W2277185438A5023956757 @default.
• W2277185438 hasAuthorship W2277185438A5058735749 @default.
• W2277185438 hasAuthorship W2277185438A5063904421 @default.
• W2277185438 hasAuthorship W2277185438A5071756814 @default.
• W2277185438 hasAuthorship W2277185438A5075566772 @default.
• W2277185438 hasAuthorship W2277185438A5085317448 @default.
• W2277185438 hasConcept C126322002 @default.
• W2277185438 hasConcept C126894567 @default.
• W2277185438 hasConcept C141071460 @default.
• W2277185438 hasConcept C143998085 @default.
• W2277185438 hasConcept C2776694085 @default.
• W2277185438 hasConcept C2776755627 @default.
• W2277185438 hasConcept C2777658100 @default.
• W2277185438 hasConcept C2778822529 @default.
• W2277185438 hasConcept C2780147359 @default.
• W2277185438 hasConcept C502942594 @default.
• W2277185438 hasConcept C71924100 @default.
• W2277185438 hasConcept C72563966 @default.
• W2277185438 hasConcept C90924648 @default.
• W2277185438 hasConceptScore W2277185438C126322002 @default.
• W2277185438 hasConceptScore W2277185438C126894567 @default.
• W2277185438 hasConceptScore W2277185438C141071460 @default.
• W2277185438 hasConceptScore W2277185438C143998085 @default.
• W2277185438 hasConceptScore W2277185438C2776694085 @default.
• W2277185438 hasConceptScore W2277185438C2776755627 @default.
• W2277185438 hasConceptScore W2277185438C2777658100 @default.
• W2277185438 hasConceptScore W2277185438C2778822529 @default.
• W2277185438 hasConceptScore W2277185438C2780147359 @default.
• W2277185438 hasConceptScore W2277185438C502942594 @default.
• W2277185438 hasConceptScore W2277185438C71924100 @default.
• W2277185438 hasConceptScore W2277185438C72563966 @default.
• W2277185438 hasConceptScore W2277185438C90924648 @default.
• W2277185438 hasIssue "14_suppl" @default.
• W2277185438 hasLocation W22771854381 @default.
• W2277185438 hasOpenAccess W2277185438 @default.
• W2277185438 hasPrimaryLocation W22771854381 @default.
• W2277185438 hasRelatedWork W1970677298 @default.
• W2277185438 hasRelatedWork W2034135911 @default.
• W2277185438 hasRelatedWork W2044328190 @default.
• W2277185438 hasRelatedWork W2054476072 @default.
• W2277185438 hasRelatedWork W2058967569 @default.
• W2277185438 hasRelatedWork W2168627855 @default.
• W2277185438 hasRelatedWork W2366392510 @default.
• W2277185438 hasRelatedWork W2418204902 @default.
• W2277185438 hasRelatedWork W2569260518 @default.
• W2277185438 hasRelatedWork W4214540119 @default.
• W2277185438 hasVolume "22" @default.
• W2277185438 isParatext "false" @default.
• W2277185438 isRetracted "false" @default.
• W2277185438 magId "2277185438" @default.
• W2277185438 workType "article" @default.